New treatments offer hope for one skin condition that often worsens in winter
As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.
Healio6h
Ruxolitinib cream 1.5% effective, safe for greater AD surface area in pediatric patients
Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...
dermatologyadvisor1d
Long-Term Lebrikizumab in AD Is Effective Despite Inadequate Short-Term Response
Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential
Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...
dermatologyadvisor2d
Monthly Tralokinumab Is an Effective Dosing Regimen in Atopic Dermatitis
Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.
Healio2d
Tralokinumab demonstrates real-world utility for atopic dermatitis
Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...
Atopic Dermatitis Affects Millions, And Johnson & Johnson Is Committed To Addressing The Unmet Needs Of Patients
AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...
Apogee Therapeutics: No Clinical Efficacy Data, Strong Competition, High Market Cap
Apogee Therapeutics develops therapies for inflammatory autoimmune diseases. Find out why I'm bearish on APGE stock.